Description

Keeping the Psychedelic Renaissance from Going Off the Rails                                                           Presented by Andrew Penn, MS, PMHNP and Charles L. Raison, MD | Director of Vail Health Behavioral Health Innovation Center. 

Some psychedelic-assisted therapies, such as psilocybin for major depression, are nearing the end of their clinical trials which may soon lead to FDA approval. Join Penn and Raison, as they explore the implications, opportunities, and challenges of this change in how we treat mental illness. 

Learn More: www.VailHealth.org/InnovationSeries

Register: InnovationSeries@VailHealth.org

Novel Approaches to Behavioral Health Innovation is a monthly lecture series offered through Vail Health Behavioral Health Innovation Center and University of Wisconsin-Madison. The series features innovative leaders in behavioral health treatment and research and offers continuing education credit for mental health professionals.